Записаться на прием


Page content:

I. Treatment and Training Programs 

«Genuine Buteyko Breathing Techniques from a Primary Source» 


1. The treatment program «Genuine Buteyko breathing techniques from a primary source for patients» 

2. The training program «Genuine Buteyko breathing techniques from a primary source for Buteyko practitioner» 

3. A combined program «Training as a Buteyko practitioner from my own experience of treatment of disease»


II. Who is Who

     Who conducts Buteyko treatment and training


III. Foreword 

     by Dr. Andrey Novozhilov, MD, Chief physician and co-founder of the Buteyko Clinic in Moscow (1987), co-author of the Buteyko method, author of the modern treatment and training programs, copyright holder


IV. Problematic Articles about the Buteyko method and Covid-19

     COVID-19: prevention and treatment, (March 29, 2020)

     COVID-19: prevention and treatment of bronchial asthma, (March 25, 2020)

     COVID-19: Why mechanical ventilation does not help? (April 16, 2020)

     COVID-19, Buteyko breathing technics and corticosteroids in October 2020 (October 17, 2020)


*******************************


I. Treatment and Training program

The treatment or training program consists of 5 lessons.

During every lesson we offer a new original Buteyko breathing technique from the original source. In the fifth lesson all the learnt techniques can be combined into one highly effective exercise for treatment and recovery, which can be performed invisibly, constantly and in any situation: at work in the office, in the gym, at a party with friends.

The imperceptible performance of the Buteyko breathing technique is the basis of the lasting sports stamina, high prevention of stress, chronic fatigue, asthma attack, increased blood pressure, allergy attack and other modern diseases.

If you do not intend to buy a full program of 5 lessons for treatment, then the information and knowledge gained even in one lesson will allow you to successfully start using the Buteyko breathing technique for treatment and recovery. 

Please contact us by email: buteyko@me.com



1. We offer the treatment program in English and Spanish

«Genuine Buteyko Breathing Techniques from Original Source for Patients»

by Dr. Anna Novozhilova, Buteyko method instructor, Director of the program «Genuine Buteyko Breathing Techniques from Original Source for Foreigners»;

The cost of one lesson is 200 euros, duration is 45 minutes;

by Dr. Andrey E.Novozhilov, MD, Chief physician and co-founder of the Buteyko Clinic in Moscow (1987), co-author of the Buteyko method, author of the modern treatment and training programs, copyright holder. 

We offer this program if you have a lot of medical questions and if you want to study Buteyko breathing technique with a medical doctor.

The cost of one lesson is 400 euros, duration is 75 minutes (including the cost and time of translation). 


*******************************


2. We offer the training program in English and Spanish

«Genuine Buteyko breathing techniques from a primary source for Buteyko practitioner»  

by Dr. Andrey Novozhilov, MD, Chief physician and co-founder of the Buteyko Clinic in Moscow (1987), co-author of the Buteyko method, author of the modern treatment and training programs, copyright holder. 

We offer this program if you do not have any diseases, but wish to become a Buteyko practitioner, hold a Specialist Certificate, work legally and receive medical advice about the Buteyko method. 


*******************************


3. We offer the combined program in English and Spanish

«Training as a Buteyko practitioner from my own experience of treatment of disease»


by Dr. Andrey Novozhilov, MD, Chief physician and co-founder of the Buteyko Clinic in Moscow (1987), co-author of the Buteyko method, author of the modern treatment and training programs, copyright holder. 

We offer this combined program if you have a disease and wish to combine your own successful treatment and training program as a Buteyko practitioner with your own experience.


*******************************

IMPORTANT INFORMATION for Buteyko practitioners!

For one year, you can use the medical support of co-author of the Buteyko method, copyright holder, the author of modern treatment and training programs, Dr. Andrey Novozhilov, which will help you acquire high professional skills as a Buteyko practitioner.


*******************************



II. Who is Who

Who conducts Buteyko treatment and training


1a.jpeg

Dr. Anna Novozhilova

Buteyko method instructor,

Director of the program «Genuine Buteyko Breathing Techniques from Primary Source for Foreigners"


Education: MGIMO University (Moscow State University of International Relations, Ministry of Foreign Affairs of Russia)


Teaches Buteyko breathing techniques since 2015 in English and Spanish.


She was trained as a teacher 

- directly by the author of the Buteyko method - Dr. Konstantin P. Buteyko, MD, PhD; founder of the Buteyko Clinic in Moscow in 1987,

- directly by Dr. Lyudmila D. Buteyko (Novozhilova), co-author of the Buteyko Method; co-founder of the Buteyko Clinic in Moscow in 1987,

- directly by Dr. Andrey E.Novozhilov, MD, Chief physician of the Buteyko Clinic in Moscow since 1989, co-author of the Buteyko method, co-founder of the Buteyko Clinic in Moscow in 1987, copyright holder. 


Anna is a goddaughter of Dr. K. Buteyko, MD, PhD.


*******************************



2a.jpeg


Dr. Andrey E. Novozhilov, M.D

Chief physician of the Buteyko Clinic since 1989,

co-founder of the Buteyko Clinic in Moscow in 1987,

co-author of the Buteyko method, 

author of the modern treatment and training programs, 

copyright holder


Education: Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation


Teaches Buteyko breathing techniques since 1968


He was trained as a teacher

- directly by the author of the Buteyko method - Dr. Konstantin P. Buteyko, MD, PhD; founder of the Buteyko Clinic in Moscow in 1987,

- directly by Dr. Lyudmila D. Buteyko (Novozhilova), co-author of the Buteyko method; co-founder of the Buteyko Clinic in Moscow in 1987


*******************************



III. Foreword



Dear Friends,

The Buteyko breathing technique known as the Buteyko method is a registered scientific medical technology for the non-drug treatment of respiratory, circulatory and immunity diseases.

The author of the Buteyko method is Dr. Konstantin P. Buteyko (MD, PhD), co-authors are Dr. Lyudmila D. Buteyko and Dr. Andrey E. Novozhilov.

The Buteyko Method can be applied by a medical doctor or a specially trained Buteyko specialist.

The Buteyko specialist must confirm his qualifications and receive a Certificate annually, otherwise his actions may be dangerous for patient.

Please, note, that the only source of genuine true knowledge about Buteyko method can only be the author and co- authors who are the creators of this technology: Dr. Konstantin P. Buteyko, Dr. Lyudmila D. Buteyko, and today me, Dr. Andrey E. Novozhilov.

In 2014, as a co-author and copyright holder, I made a decision on the Buteyko specialists annual certification to confirm the qualifications of the Buteyko specialists. It also provides my professional medical support and continuing education.

As a medical doctor, co-author, copyright holder, I confirm that any Diplomas, Certificates, etc. signed by me or by Dr. Buteyko himself, which are older than one year, are now a historical artifact, museum value, but cannot be the basis for using the Buteyko method without annual certification and proof of qualifications.

As a medical doctor, co-author and copyright holder, I affirm that it is impossible to be a representative of the Buteyko Method or Buteyko Clinic in Moscow without the annual certification of a Buteyko specialist and confirmation of qualifications.

Make sure that your Buteyko specialist has a Certificate with my signature not older than one year, confirming his high Buteyko qualification.

Make sure that any material (books, articles, video tutorials, etc.) describing or demonstrating Buteyko breathing exercises has on the first page the Preface of the copyright holders or the Consent to publication, otherwise such material usually contains errors, absurdities and threat to health.


Warm regards,

Dr. Andrey Novozhilov, MD, Chief physician of the Buteyko Clinic in Moscow (since 1989), 

co-author of the Buteyko method, 

author of the modern treatment and training programs, 

co-founder of the Buteyko Clinic in Moscow in 1987,

copyright holder. 


*******************************






IV. Problematic articles about Buteyko method and covid-19  



COVID-19: prevention and treatment

Dr. Andrey Novozhilov, MD, Chief physician of the Buteyko Clinic in Moscow (since 1989), 

co-author of the Buteyko method, 

co-founder of the Buteyko Clinic in Moscow in 1987


March 29, 2020


1. The cause of Acute Respiratory Distress Syndrome (ARDS)

2. Prevention of acute respiratory distress syndrome (ARDS)

Anti-inflammatory and immunosuppressive effects of corticosteroids

Anti-inflammatory effect of normalising carbon dioxide in the lungs

The value of normalisation of the constant alveolar CO2 (pCO2A2)

CO2 measurement in the lungs

Cause of CO2 deficiency in the lungs

The methods of CO2 normalisation in the lungs using Buteyko

3. Treatment of respiratory failure under COVID-19 according to the method proposed by Dr. Konstantin P. Buteyko (M.D, Ph.D)

Prevention and treatment of cell hypoxia

Prevention and treatment of arterial hypoxemia

Prevention and treatment of cell and arterial hypercapnia

Acute respiratory distress syndrome (ARDS) prevention with Buteyko method

Danger of mechanical ventilation

Limiting the effectiveness of oxygen therapy

4. Prevention of respiratory failure under COVID-19 according to the method proposed by Dr. Buteyko

5. SARS-CoV-2 and COVID-19: a natural mechanism for the prevention of infection


Coronavirus (lat. Coronaviridae) infection COVID-19 (Corona virus disease 2019) is an acute infection caused by the SARS-CoV-2 coronavirus (Severe Acute Respiratory Syndrome), which can occur in the form of an acute respiratory infection with complications in viral pneumonia and acute respiratory distress syndrome (Acute Respiratory Distress Syndrome - ARDS).

COVID-19 can be stopped at an early stage of development and it is possible to prevent acute respiratory distress syndrome (ARDS), which is the leading cause of death, regardless of the patient's age or associated chronic diseases.



1. The cause of Acute Respiratory Distress Syndrome (ARDS)

Acute respiratory distress syndrome (ARDS) is developed as a result of a strong immune response to virus invasion and the onset of acute diffuse pneumonia.

In the initial (exudative) phase of diffuse pneumonia, anti-inflammatory substances are released that damage the capillaries and alveoli. As a result the exudate penetrates the alveolar air space, which damages the lungs and disrupts gas exchange.

Activation of the immune response by the virus and high release of anti-inflammatory substances are one of the causes of acute lung damage and the development of ARDS.


2. Prevention of Acute Respiratory Distress Syndrome (ARDS)

It can be assumed that a decrease in the early stage of the speed of development of diffuse pneumonia increases the time during which the immune response is being developed, which reduces the strength of the immune response and the likelihood of acute respiratory distress syndrome (ARDS).

There is also the possibility of preventing the activation of the immune response or reducing its strength with the help of immunosuppressive drugs.

Long-term clinical observation of the effectiveness of corticosteroids demonstrates the undoubted anti-inflammatory effect of their use in small doses, as well as the immunosuppressive effect of corticosteroids in large doses in combination with their anti-inflammatory effect in the initial stage of use.


Anti-inflammatory and immunosuppressive effect of corticosteroids

Anti-inflammatory effect of corticosteroids in low-dose

After confirmation of infection with the SARS-CoV-2 virus or at the first symptoms of acute respiratory viral infection (ARVI), the prophylactic use of corticosteroids in small doses due to their anti-inflammatory effect reduces the likelihood of acute diffuse pneumonia and acute respiratory distress syndrome.

For example: 1-12 milligrams per day of triamcinolone in tablets (1 / 4-3 tablets) for 1-3-5 days.

The therapeutic use of corticosteroids in small doses that do not inhibit the immune system in the early phase of acute diffuse pneumonia due to their anti-inflammatory effect reduces the speed of development of the inflammatory process, which increases the time for which the immune response develops, thereby reducing the strength of the immune response and the likelihood of acute respiratory distress syndrome.

For example: 4-20 milligrams per day of triamcinolone in tablets (1-5 tablets) for 1-3-5 days.


Immunosuppressive and anti-inflammatory effect of corticosteroids

It is also known that high doses of corticosteroids with relatively long-term use inhibit our immunity. It allows to use them as immunosuppressants with a powerful anti-inflammatory effect in the initial phase of use.

For example: more than 20 milligrams per day of Triamcinolone in tablets (more than 5 tablets) during 1-2 weeks or more.

Correction of the dose of corticosteroids should be made daily in the direction of increase or decrease according to "clinical need".

If there is a risk of secondary bacterial infection, the use of appropriate antibiotics is justified.


Normalisation of carbon dioxide1 in the lungs has an anti-inflammatory effect


The value of normalisation of the constant alveolar CO2 (pCO2A2)


Over the course of several decades, we have been observing an undoubted anti-inflammatory effect resulting from the normalisation of external respiration function and CO2 pressure in the lungs in patients with various types of inflammatory respiratory diseases.

Based on this, it can be assumed that, at an early stage of COVID-19 disease, it is possible to prevent the development of acute diffuse pneumonia under the condition of complete normalisation of the partial pressure of carbon dioxide (CO2) in the alveolar air of the lungs (pCO2A) according to the method proposed by the Dr. Konstantin P. Buteyko (MD, PhD) more than half a century ago.

Long-term clinical observation proved the undoubted anti-inflammatory effect of the normalisation of this key constant of homeostasis in the treatment of mixed inflammatory diseases of the respiratory tract.

For example, partial normalisation of pCO2A to 32 millimetres of mercury (at a norm of 40 mm Hg) allows in a short time to eliminate bronchial obstruction, asthma and to cancel drug treatment. It becomes possible as a result of a decrease in the activity of allergic inflammation of the bronchi, which could be aggravated by viral or microbial infection.


CO2 measurement in the lungs

To measure alveolar CO2 (pCO2A), Dr. Buteyko proposed a simple method, according to which the duration of a spontaneous delay in breathing after exhalation (if performed without volitional effort) exactly corresponds to a certain value of CO2 in the lungs.

A reliable indicator of the lack of the volitional effort when holding a breath is the normal depth or the normal amplitude of the first inhale after it is completed.

The duration in seconds of breath holding allows to determine CO2 in the lungs according to a special Buteyko table (in volume percent or millimetres of mercury - mm Hg).

The duration of breath holding of more than 45 seconds, if it is performed without volitional effort, corresponds to the normal pressure of CO2 in the lungs (40 mmHg), and then it is impossible to determine any signs of inflammatory disease of the respiratory system.


The cause of CO2 deficiency in the lungs

The main reason for the decrease in CO2 in the lungs (alveolar hypocapnia) is pulmonary hyperventilation3, the elimination of which allows you to quickly normalise the constant of CO2 and successfully treat inflammatory diseases of the respiratory system of any origin.

A clinical sign of excessive ventilation of the lungs and alveolar hypocapnia are bronchial obstruction4 resulting from a decrease in pCO2A of less than 28 mm Hg and arterial hypertension5 resulting from peripheral angiospasm.


The methods of CO2 normalisation in the lungs using Buteyko

In order to eliminate hyperventilation and normalise CO2 in the lungs, Dr. Buteyko proposed a simple method, based on a slight decrease in the depth (amplitude) of breathing with volitional effort in order to create a feeling of a slight lack of air for 1-2 minutes.

It is also possible to normalise CO2 in the lungs using a series of short breath holdings after exhalation, performed with a slight volitional effort.

A positive result is the elimination of negative symptoms of the disease or an undoubted increase in the duration of breath holding during 5-10 minutes of exercise, which indicates a partial elimination of CO2 deficiency.

For example, the patient is offered to perform a series of short breath holdings of not more than 5 seconds after exhalation with an interval of at least 1 minute.

In our practice, there was a case of the complete elimination of the symptoms of the long-term bronchial obstruction during two weeks of self-tuition, when the patient, on the recommendation of a doctor, performed over 200 short breath-holdings of not more than 5-10 seconds each after exhalation during the day.

Another way of Buteyko self-studying implies reducing the depth of breathing in an easily tolerated volume with the help of the slight effort within 1-2 minutes after a short breath hold not exceeding 5-10 seconds and performed after exhalation.

The treatment method proposed by Dr. Buteyko and based on the normalisation of external respiration has two features:

A / elimination of hyperventilation of the lungs is carried out by the patient himself using volitional effort, since, for example, inhaling a gas mixture with a high content of CO2 has many nuances and does not give the expected effect due to the preservation of pulmonary hyperventilation;

B / given the certain technical complexity of normalising breathing as a method of treatment, the teacher of the Buteyko method should have the confirmation of his/her proficiency and qualification directly from me as a co-author of the invention and copyright holder.


3. Treatment of respiratory failure under COVID-19 according to the method proposed by Dr. Konstantin P. Buteyko (M.D, Ph.D)

Respiratory failure is a violation of the normal gas composition of blood and cells, which with COVID-19 occurs due to prolonged hyperventilation of the lungs, impaired patency of the bronchi, an increase in uneven ventilation, changes in the pH of arterial blood and fragmentary destruction of the lung tissue.

According to various researchers, the area of gas exchange in the lungs of an adult is about 100 square meters. A huge area of gas exchange provides the metabolic needs for oxygen with varying degrees of physical activity: from severe physical inactivity to professional sports. During breathing, the metabolism that happens (takes place) in the cells of the body receives oxygen and gets rid of carbon dioxide, which is the final product of metabolism.

Respiration is the gas exchange between the cells of the body and the air, and the movement of respiratory gases is the main regulator of the pH of blood and cells.

A number of diseases lead to fragmented destruction of the lung tissue and a decrease in the gas exchange area to 1/4 of the original, which reduces the efficiency of gas exchange in the lungs, primarily affects the ability to perform physical activity and gradually reduces the quality of life.


Prevention and treatment of cell hypoxia

Hyperventilation of the lungs, characteristic of the acute phase of respiratory diseases, reduces the partial pressure of carbon dioxide in the lungs (pCO2A), in arterial blood (pCO2a), in cells.

Hypocapnia (CO2 deficiency) at all levels changes the pH of the blood and disrupts the dissociation (decomposition) of oxyhemoglobin, which complicates the transfer of oxygen into cells and creates cellular hypoxia.

The effect, as a result of which the blood is completely saturated with oxygen, but at the same time there is a deficiency of oxygen in the cells at the metabolic level, was first discovered by Russian scientist, professor Bronislav Verigo in 1898, rediscovered by Danish scientist Christian Bohr in 1904 and was called the Verigo-Bohr effect.

At this stage of the disease, normalisation of external respiration according to the method proposed by Dr. Buteyko allows:

- eliminate pulmonary hyperventilation, eliminate alveolar, arterial, cellular hypocapnia;

- elimination of arterial hypocapnia will allow to normalise the pH of arterial blood, dissociation of oxyhemoglobin and to eliminate effectively cellular hypoxia.


Prevention and treatment of arterial hypoxemia

Scientific research of a Russian doctor and scientist Konstantin P. Buteyko (M.D, Ph.D) showed that excess breathing, in which there is an increase in general ventilation of the lung relative to the needs of metabolism, violates bronchial patency, creates uneven ventilation, reduces the area of ​​gas exchange, which significantly reduces its effectiveness.

Alveolar CO2 deficiency (alveolar hypocapnia) resulting from pulmonary hyperventilation creates a functional (reversible) hypocapnic bronchoconstrictor effect (a decrease in airway clearance due to bronchospasm), which, together with other elements of latent bronchial obstruction (edema of the bronchi and hypersecretion of sputum) violates bronchial patency, creates uneven ventilation of the lungs and reduces the area of ​​gas exchange, which may be the cause of a decrease in oxygen pressure in the arterial first blood (arterial hypoxemia).

Arterial hypoxemia joins cellular hypoxia, and cell and arterial hypercapnia (excess CO2) begins to develop as a result of a decrease in gas exchange efficiency.


At this stage of the disease, normalisation of external respiration according to the method proposed by Dr. Buteyko allows:

- eliminate pulmonary hyperventilation and elements of latent bronchial obstruction resulting from alveolar hypocapnia;

- normalisation of bronchial patency allows you to normalise the gas exchange area and eliminate arterial hypoxemia, eliminate the initial cell and arterial hypercapnia;

- elimination of arterial hypo- or hypercapnia normalises the pH of arterial blood, the breakdown of oxyhemoglobin and eliminates cellular hypoxia.


Prevention and treatment of cell and arterial hypercapnia

A functional decrease in the efficiency of gas exchange as a result of pulmonary hyperventilation at the initial stage of the disease in a short time gets negative development as a result of lung destruction in response to the invasion of the virus.

The destruction of lung tissue additionally reduces the area and efficiency of gas exchange in the lungs, which can be the cause of an increase in arterial hypoxemia, significant cellular and arterial hypercapnia, and death of the patient.


At this stage of the disease, normalszation of external respiration according to the method proposed by Dr. Buteyko allows:

- eliminate pulmonary hyperventilation and elements of latent bronchial obstruction resulting from alveolar hypocapnia, which will ensure normal gas exchange through intact areas of the lungs and will quickly eliminate significant cellular and arterial hypercapnia;

- normalisation of gas exchange through intact areas of the lungs will eliminate arterial hypoxemia;

- elimination of arterial hypercapnia normalises the pH of arterial blood, the breakdown of oxyhemoglobin and will eliminate cellular hypoxia.


Acute respiratory distress syndrome (ARDS) prevention with Buteyko method

After confirmation of infection with the SARS-CoV-2 virus or at the first symptoms of acute respiratory viral infection (ARVI), the use of small doses of corticosteroids immediately due to their anti-inflammatory effect reduces the likelihood of acute diffuse pneumonia.

In the case of acute pneumonia, the use of corticosteroids reduces the speed of development of the inflammatory process, which increases the time during which the immune response is formed, thereby reducing the force of the immune response and the likelihood of acute respiratory distress syndrome.


At this stage of the disease, normalisation of external respiration according to the method proposed by Dr. Buteyko allows:

- eliminate pulmonary hyperventilation and alveolar hypocapnia, which, as shown by many years of clinical practice, with pCO2A 40 mm Hg makes inflammation of the airways impossible.

A sensible combination of corticosteroids and normalisation of external respiration with the help of Buteyko method will make airway inflammation impossible.


Danger of mechanical ventilation

Mechanical ventilation is used to compensate for respiratory failure, normalise the gas composition of blood and cells.

Relatively safe while maintaining disputable effectiveness may be the mechanical ventilation of the lungs with a small volume of air at low pressure, with the settings as close as possible to the physiological norm of a state of rest.


1. The main danger of mechanical lung ventilation is the prolonged hyperventilation of the lungs, which makes the ventilator procedure dangerous and low effective.

Hyperventilation of the lungs creates alveolar and, at the initial stage, arterial hypocapnia, which changes the pH of the blood and causes cellular hypoxia.

Alveolar hypocapnia creates a hypocapnic bronchoconstrictor effect, which with other elements of latent bronchial obstruction significantly reduces the gas exchange area and can be the cause of arterial hypoxemia.

At this stage, arterial hypocapnia gradually turns into hypercapnia as a result of a decrease in the area and efficiency of gas exchange.


2. Appearance of hidden bronchial obstruction, increasing unevenness of ventilation and acute death of the lungs (acute respiratory distress syndrome - ARDS) do not allow the necessary gas exchange through intact lung areas to eliminate cell and arterial hypercapnia.


3. As a result, the prolonged hyperventilation of the lungs, which does not allow normalisation of gas constants, makes the area of ​​ventilation of the lungs excessive in relation to metabolism and leads to the rapid development of pneumofibrosis as a compensatory reaction of respiratory homeostasis.


Limiting the effectiveness of oxygen therapy

Breathing with a gas mixture with a high oxygen content is intended to increase the saturation of arterial blood and body cells with oxygen.

Nevertheless, it is known that blood is always and under any conditions, including with a significant decrease in the area of ​​the ventilated surface of the lungs, completely saturated with oxygen, that is, all hemoglobin, which is a physical carrier of oxygen, is occupied.

The cause of arterial hypoxemia may be insufficient intake of air into the gas exchange zone.

Hyperventilation of the lungs, creating a hypocapnic bronchoconstrictor effect, increases the unevenness of ventilation of the lungs, violates the patency of the bronchi, forms elements of extensive hidden bronchial obstruction, which may be the main reason for the decrease in oxygen in arterial blood (arterial hypoxemia).

An oxygen supply which surpasses physiological norm and the normal rate of breathing volume per minute (for example, 10 litres per minute with a norm of 5.3 l/min), will always give a negative result and an increase in arterial hypercapnia. The cause is the hyperventilation of the lungs and hypocapnic (alveolar) bronchoconstrictor effect which sharply reduces the area of ​​gas exchange in the lungs.


At this stage of the disease, normalisation of external respiration according to the method proposed by Dr. Buteyko normalises bronchial patency, increases the gas exchange area, including through intact areas of the lungs, which is especially important under COVID-19 and normalises arterial blood oxygenation in a natural way.

In most cases, the fact that the transition of oxygen from blood to cells is regulated by the pH of the blood, and not by the degree of saturation of the blood with oxygen, is overlooked.

Under normal conditions, hyperventilation of the lungs during 10 minutes, creating a deficiency of CO2 in the lungs and blood, leads to a change in blood pH and a violation of the dissociation of oxyhemoglobin, which leads to a paradoxical situation: the blood is completely saturated with oxygen, since gas exchange in the lungs is not disturbed, but oxygen does not enter the cells and  tissue, and cellular hypoxia occurs, which cannot be eliminated without normalising the pH of the blood (Verigo-Bohr effect).

An insignificant clinical effect resulted from the oxygen breathing may be due to an increase in oxygen in the blood plasma, while in order to effectively eliminate cellular hypoxia, it is necessary to normalise the blood pH and general ventilation.


4. Prevention of respiratory failure according to the method proposed by Dr. Buteyko


To prevent cellular hypoxia, arterial hypoxemia, cellular and arterial hypercapnia, it is enough to eliminate pulmonary hyperventilation and normalise external respiration according to the method proposed by Dr. Buteyko.


1. In the absence of damage to the lung tissue, gas exchange is normalised as a result of elimination of elements of latent bronchial obstruction, normalisation of blood pH and normal dissociation of oxyhemoglobin.


2. In the event of damage to any area of ​​the lung tissue, gas exchange will be carried out in sufficient volume through healthy areas in the absence of latent bronchial obstruction and normal arterial blood pH.


Restore breathing through the nose in full, eliminate noisy and deep breathing through the mouth, put a patient with respiratory failure on his stomach to limit excursion of the chest and abdomen and to reduce pulmonary hyperventilation - these measures will have a greater positive effect than mechanical ventilation and oxygen therapy.



5. SARS-CoV-2 and COVID-19: a natural mechanism for the prevention of infection


Despite the high contagiousness6 of the virus, for viral and microbial infection our breathing through the nose is a natural, difficult to overcome barrier.

The main rule for the prevention of infectious diseases is to stop the transmission of infection, to break the path of transmission of the pathogen.


It should be remembered that you need to breathe exclusively through the nose while relaxed as well as while doing physical activity, particularly when doing sport.

The nose performs three essential functions: the air warms up, the air is disinfected, the air is moistened.


Years long analysis of cases of disease incidence has convincingly shown that the main reason for the spread of viral infection is breathing through the open mouth.

For example, children, in the process of treating bronchial asthma according to the method proposed by Buteyko, form a persistent habit to breathe through the nose, especially when doing physical exercises. It reduces the number of cases of acute respiratory viral infection (ARVI) and influenza by 50% in a short time.


Explanation of terms

1. Carbon dioxide, CO2 - one of the respiratory gases, whose constant value maintenance in the cells, in the blood, in the lungs along with oxygen (O2) ensures the performance of the functional respiratory system. The normal content of CO2 in the lungs is ensured by metabolic activity and the functioning of the external respiration system.

The movement of respiratory gases is the main regulator of the acid-base balance (pH) of the body.

2. pCO2A is the partial pressure of carbon dioxide in the alveolar air of the lungs.

3. Hyperventilation of the lungs - an increase in general ventilation of the lungs in relation to the needs of metabolism. It is determined by the development of deficiency of the final metabolic product - CO2, which is removed through the lungs during breathing.

4. Bronchial obstruction - a decrease of the diameter (lumen) of the bronchi as a result of edema, excessive sputum and spasm. In some diseases, it is reversible.

5. Arterial hypertension - an increase in blood pressure, most often occurs as a result of compression of peripheral vessels (peripheral angiospasm).

6. Contagiousness - the property of infection is transmitted from patients to healthy. 


March 29, 2020





COVID-19: prevention and treatment of bronchial asthma

Dr. Andrey Novozhilov, MD, Chief physician of the Buteyko Clinic in Moscow (since 1989), 

co-author of the Buteyko method, 

co-founder of the Buteyko Clinic in Moscow in 1987


March 25, 2020


Coronavirus (lat. Coronaviridae) infection COVID-19 (Corona virus desese 2019) is an acute infection caused by the SARS-CoV-2 coronavirus (Severe Acute Respiratory Syndrome), which can occur in the form of an acute respiratory infection with complications in viral pneumonia and acute Acute Respiratory Distress Syndrome (ARDS), which is the leading cause of death.


Cause of Acute Respiratory Distress Syndrome (ARDS)

After infection, the SARS-CoV-2 virus spreads through the respiratory tract, causing a strong immune response in the body, a large release of cytokines and a decrease in the number of lymphocytes.

In the initial exudative phase of diffuse pneumonia, cytokines and other anti-inflammatory substances are released that damage the capillaries and alveoli, as a result of which the exudate penetrates the alveolar air space, which damages the lungs and disrupts gas exchange.

A strong immune response of the body and a large release of cytokines are one of the causes of acute lung damage and the development of ARDS.


ARDS Prevention

To prevent acute lung damage, it is necessary to reduce the intensity of the immune response. It means that at the initial stage of COVID-19, it is necessary to prevent the development or to decrease the development  rate of diffuse pneumoniawith low doses of corticosteroids and to normalize the pressure of carbon dioxide in the alveoli (pCO2A) according to the method proposed by Dr. Konstantin Buteyko (MD, PhD).


COVID-19: prevention of ARDS in patients with asthma

According to the information of Federal Medical and Biological Agency of Russia dated on March 23, 2020, there have been created test systems which allow you to very quickly receive an answer about infection with the SARS-CoV-2 virus and about the beginning of the body's immune response. It is at the initial stage of the disease that the proposed treatment will have the maximum effect.


1. Corticosteroids in small doses 

A/. The use of corticosteroids in the initial stage of the disease COVID-19 is an effective prevention of a possible exacerbation of asthma as a result of a viral infection.

The early use of corticosteroids (before the onset of clinical signs of exacerbation of asthma) can significantly reduce their dosage and duration of use.

B /. The use of corticosteroids in small doses that do not inhibit the immune system will preventively reduce the rate of pneumonia, which will prevent a strong immune response of the body, acute lung damage and the development of ARDS.

For example, the daily dose of Triamcinolone (Triamcinolone) from 4 to 24 milligrams in tablets with daily correction in the direction of increasing or decreasing "according to the clinical picture" allows, according to the results of many years of clinical observations, within 1-3-5 days to obtain an undoubted improvement in the treatment of diseases with a mixed nature of airway inflammation, for example, with exacerbation of bronchial asthma resulting from a viral or microbial infection.


2. Normalization of pressure of carbon dioxide in the lungs (pCO2A) using Buteyko 

There is a possibility at the early stage of COVID-19 disease to prevent the development of diffuse pneumonia under the condition of partial or complete normalization of the partial pressure of carbon dioxide in the alveolar air of the lungs (pCO2A) according to the method proposed by Dr. K. Buteyko.

Over the course of several decades, we have been witnessing an undoubted anti-inflammatory effect as a result of the normalization of this key constant of homeostasis in the treatment of respiratory diseases.

For example, partial normalization of CO2 in the lungs to 32 millimeters of mercury (with a norm of 40 mm Hg) allows within short time to eliminate the symptoms of bronchial asthma and cancel drug treatment (including steroids) due to a decrease in the activity of allergic inflammation of the bronchi, the aggravation of which was caused by a viral or microbial infection.

To measure alveolar CO2 (pCO2A), Dr. K. Buteyko proposed a very simple method, according to which the duration of a spontaneous delay in respiration after exhalation (in seconds) corresponds to a specific content of CO2 in the lungs.

The main cause of alveolar hypocapnia is hyperventilation of the lungs, the elimination of which allows you to quickly normalize external respiration and the CO2 constant in the lungs.


The treatment method proposed by Dr. K. Buteyko has two specific details:

A / elimination of hyperventilation of the lungs is carried out by the patient himself using volitional effort, since, for example, inhaling a gas mixture with a high content of CO2 has many nuances and does not give the expected effect due to the preservation of pulmonary hyperventilation;

B / given the certain technical complexity of normalizing breathing as a method of treatment, the teacher of the Buteyko method should have the confirmation of his/her proficiency and  qualifications directly from me as a co-author of the invention and copyright holder.


3. Corticosteroids and Buteyko method (buteyko breathing technique) - double effect 

The combination of small doses of corticosteroids and the normalization of external respiration by Buteyko at the initial stage of COVID-19 can effectively prevent exacerbation of bronchial asthma as a result of a viral infection, effectively preventdiffuse pneumonia in patients with asthma and other risk groups, and in case of its occurrence, prevent strong immune response, acute lung tissue damage and the development of ARDS.

March 25, 2020




COVID-19: why mechanical ventilation does not help?

Dr. Andrey Novozhilov, MD, Chief physician of the Buteyko Clinic in Moscow (since 1989), 

co-author of the Buteyko method, 

co-founder of the Buteyko Clinic in Moscow in 1987


April 16, 2020



1. In New York, 80% of COVID-19 patients who are connected to mechanical ventilation devices die, the reason is unclear

2. Long-term hyperventilation of the lungs is the cause of high mortality on the ventilator with COVID-19

3. Treatment of respiratory failure with COVID-19 according to the method proposed by KP Buteyko

Prevention and treatment of cell hypoxia

Prevention and treatment of arterial hypoxemia

Prevention and treatment of cell and arterial hypercapnia

Danger of mechanical ventilation

Limiting the effectiveness of oxygen therapy

Cause of acute lung damage with COVID-19

Prevention of acute respiratory distress syndrome (ARDS) with COVID-19

4. Prevention of respiratory failure with COVID-19 according to the method proposed by KP Buteyko



1. In New York, 80% of COVID-19 patients who are connected to mechanical ventilation devices die, the reason is unclear

Mechanical ventilation is used to compensate for respiratory failure in patients with COVID-19, meanwhile, according to media reports, there is an extremely high mortality rate for patients connected to the ventilator.


Associated Press 

April 10, 2020 reports that “according to the Associated Press news agency in New York, 80% of COVID-19 patients who are connected to mechanical lung ventilation are dying. At the same time, the usual mortality rate for patients with difficulty breathing is 40-50%, the agency indicates with reference to data from federal and local authorities.

A small study showed a mortality rate of 86% in Wuhan, China, and one report in the UK reports 66% deaths among patients with COVID-19 connected to ventilators.


The cause of this mortality is unclear.


Chinese doctors in February expressed doubt about the effectiveness of mechanical ventilation, since intensive breathing only worsened lung function, and intubation carried additional risks for a seriously ill patient.

At the same time, doctors are trying alternative methods of treatment, for example, laying the patient in such poses so that different parts of the lungs can open better or use an apparatus for invasive extracorporeal oxygen saturation of the blood. ”


newspaper.ru

On April 10, 2020, in an interview with doctors, they reported "about ventilator-associated lung injuries, knowing about which, resuscitation doctors choose sparing modes, small tidal volumes, and try not to force an increase in airway pressure."

It is reported that “in a patient with COVID-19, the oxygen tension in the blood decreases as a result of damage to the virus over a large area of ​​the lungs, which ceases to transmit oxygen from the outside to the blood, compensatory shortness of breath occurs. In such a situation, the patient’s coup from the back to the stomach leads to the fact that the fluid accumulated in the lungs does not compress the lungs, does not affect gas exchange and allows you to survive a critical situation. ”


2. Long-term hyperventilation of the lungs is the cause of high mortality on the ventilator under COVID-19

The cause of high mortality in mechanical ventilation with COVID-19 is prolonged hyperventilation.


In a normal situation, lung ventilation, significantly exceeding normal values, can lead to the death of a healthy person within 10 minutes.


At the beginning of the last century, during the period of rapid scientific discoveries in physiology, laboratory studies on animals showed an amazing phenomenon: excessive ventilation of the lungs for several minutes leads to the death of a completely healthy laboratory animal.

However, they were able to explain this phenomenon only after 70 years, thanks to the scientific research of a Russian doctor and scientist Konstantin P. Buteyko (M.D, Ph.D).


Under normal conditions, in a healthy person, hyperventilation of the lungs for 10 minutes can reduce the pressure of carbon dioxide (CO2) in the lungs, arterial blood, and cells to a level incompatible with life, as a result of which the body dies or compensatory reactions of the respiratory system arise, whose action will be aimed at normalizing gas constants (constant values ​​for oxygen and carbon dioxide) and respiratory homeostasis as a whole.

The most striking reactions whose action is aimed at normalizing respiratory homeostasis are reversible bronchial obstruction and an asthma attack in patients with asthma or spasm of blood vessels and an increase in blood pressure, as well as a prolonged respiratory arrest in sleep (apnea) in a snoring person.



3. Treatment of respiratory failure under COVID-19 according to the method proposed by Dr. Buteyko

Respiratory failure is a violation of the normal gas composition of blood and cells, which with COVID-19 occurs due to prolonged hyperventilation of the lungs, impaired patency of the bronchi, an increase in uneven ventilation, changes in the pH of arterial blood and fragmentary destruction of the lung tissue.


According to various researchers, the area of gas exchange in the lungs of an adult is about 100 square meters. A huge area of gas exchange provides the metabolic needs for oxygen with varying degrees of physical activity: from severe physical inactivity to professional sports. During breathing, the metabolism that happens (takes place) in the cells of the body receives oxygen and gets rid of carbon dioxide, which is the final product of metabolism.

Respiration is the gas exchange between the cells of the body and the air, and the movement of respiratory gases is the main regulator of the pH of blood and cells.


A number of diseases lead to fragmented destruction of the lung tissue and a decrease in the gas exchange area to 1/4 of the original, which reduces the efficiency of gas exchange in the lungs, primarily affects the ability to perform physical activity and gradually reduces the quality of life.


Prevention and treatment of cell hypoxia

Hyperventilation of the lungs, characteristic of the acute phase of respiratory diseases, reduces the partial pressure of carbon dioxide in the lungs (pCO2A), in arterial blood (pCO2a), in cells.

Hypocapnia (CO2 deficiency) at all levels changes the pH of the blood and disrupts the dissociation (decomposition) of oxyhemoglobin, which complicates the transfer of oxygen into cells and creates cellular hypoxia.

The effect, as a result of which the blood is completely saturated with oxygen, but at the same time there is a deficiency of oxygen in the cells at the metabolic level, was first discovered by Russian scientist, professor Bronislav  Verigo in 1898, rediscovered by Danish scientist Christian Bohr in 1904 and was called the Verigo-Bohr effect.


At this stage of the disease, normalization of external respiration according to the method proposed by Dr. Buteyko allows:

- eliminate pulmonary hyperventilation, eliminate alveolar, arterial, cellular hypocapnia;

- elimination of arterial hypocapnia will allow normalizing the pH of arterial blood, dissociation of oxyhemoglobin and effectively eliminating cellular hypoxia.


Prevention and treatment of arterial hypoxemia

Scientific research of a Russian doctor and scientist Konstantin P. Buteyko (M.D, Ph.D) showed that excess breathing, in which there is an increase in general ventilation of the lung relative to the needs of metabolism, violates bronchial patency, creates uneven ventilation, reduces the area of ​​gas exchange, which significantly reduces its effectiveness.


Alveolar CO2 deficiency (alveolar hypocapnia) resulting from pulmonary hyperventilation creates a functional (reversible) hypocapnic bronchoconstrictor effect (a decrease in airway clearance due to bronchospasm), which, together with other elements of latent bronchial obstruction (edema of the bronchi and hypersecretion of sputum) bronchi, creates uneven ventilation of the lungs and reduces the area of ​​gas exchange, which may be the cause of a decrease in oxygen pressure in the arterial first blood (arterial hypoxemia).

Arterial hypoxemia joins cellular hypoxia, and cell and arterial hypercapnia (excess CO2) begins to develop as a result of a decrease in gas exchange efficiency.


At this stage of the disease, normalization of external respiration according to the method proposed by Dr. Buteyko allows:

- eliminate pulmonary hyperventilation and elements of latent bronchial obstruction resulting from alveolar hypocapnia;

- normalization of bronchial patency allows you to normalize the gas exchange area and eliminate arterial hypoxemia, eliminate the initial cell and arterial hypercapnia;

- elimination of arterial hypo- or hypercapnia normalizes the pH of arterial blood, the breakdown of oxyhemoglobin and eliminates cellular hypoxia.


Prevention and treatment of cell and arterial hypercapnia

A functional decrease in the efficiency of gas exchange as a result of pulmonary hyperventilation at the initial stage of the disease in a short time gets negative development as a result of lung destruction in response to the invasion of the virus.

The destruction of lung tissue additionally reduces the area and efficiency of gas exchange in the lungs, which can be the cause of an increase in arterial hypoxemia, significant cellular and arterial hypercapnia, and death of the patient.


At this stage of the disease, normalization of external respiration according to the method proposed by Dr. Buteyko allows:

- eliminate pulmonary hyperventilation and elements of latent bronchial obstruction resulting from alveolar hypocapnia, which will ensure normal gas exchange through intact areas of the lungs and will quickly eliminate significant cellular and arterial hypercapnia;

- normalization of gas exchange through intact areas of the lungs will eliminate arterial hypoxemia;

- elimination of arterial hypercapnia normalizes the pH of arterial blood, the breakdown of oxyhemoglobin and will eliminate cellular hypoxia.



Cause of acute lung damage under COVID-19

Coronavirus (lat. Coronaviridae) infection COVID-19 (Corona virus disease 2019) is an acute infection caused by the SARS-CoV-2 coronavirus (Severe Acute Respiratory Syndrome), which can occur in the form of an acute respiratory infection with complications in viral pneumonia and acute respiratory distress syndrome (Acute Respiratory Distress Syndrome - ARDS).


Acute respiratory distress syndrome (ARDS) develops as a result of a strong immune response to virus invasion and the onset of acute diffuse pneumonia.


In the initial (exudative) phase of diffuse pneumonia, anti-inflammatory substances are released that damage the capillaries and alveoli, as a result of which the exudate penetrates the alveolar air space, which damages the lungs and disrupts gas exchange.


Activation of a strong immune response by the virus and a large release of anti-inflammatory substances are one of the causes of acute lung damage and the development of ARDS.



Prevention of acute respiratory distress syndrome (ARDS) under COVID-19

The acute respiratory distress syndrome (ARDS) that occurs with COVID-19 can be prevented or stopped at an early stage of development by reducing the activity and inhibiting the development of pneumonia with corticosteroids in small doses and normalizing the pressure of carbon dioxide in the lungs (pCO2A) by the method proposed by Dr. Konstantin P. Buteyko (M.D, Ph.D).



Danger of mechanical ventilation

Mechanical ventilation is used to compensate for respiratory failure, normalize the gas composition of blood and cells.

Relatively safe while maintaining disputable effectiveness may be the mechanical ventilation of the lungs with a small volume of air at low pressure, with the settings as close as possible to the physiological norm of a state of rest.


1. The main danger of mechanical lung ventilation is prolonged hyperventilation of the lungs, which makes the ventilator procedure dangerous and low effective.


Hyperventilation of the lungs creates alveolar and, at the initial stage, arterial hypocapnia, which changes the pH of the blood and causes cellular hypoxia.


Alveolar hypocapnia creates a hypocapnic bronchoconstrictor effect, which with other elements of latent bronchial obstruction significantly reduces the gas exchange area and can be the cause of arterial hypoxemia.

At this stage, arterial hypocapnia gradually turns into hypercapnia as a result of a decrease in the area and efficiency of gas exchange.


2. Appearance of hidden bronchial obstruction, increasing unevenness of ventilation and acute death of the lungs (acute respiratory distress syndrome - ARDS) do not allow the necessary gas exchange through intact lung areas to eliminate cell and arterial hypercapnia.


3. As a result, prolonged hyperventilation of the lungs, which does not allow normalization of gas constants, makes the area of ​​ventilation of the lungs excessive in relation to metabolism and leads to the rapid development of pneumofibrosis as a compensatory reaction of respiratory homeostasis.


Limiting the effectiveness of oxygen therapy

Breathing with a gas mixture with a high oxygen content is intended to increase the saturation of arterial blood and body cells with oxygen.


Nevertheless, it is known that blood is always and under any conditions, including with a significant decrease in the area of ​​the ventilated surface of the lungs, completely saturated with oxygen, that is, all hemoglobin, which is a physical carrier of oxygen, is occupied.


The cause of arterial hypoxemia may be insufficient intake of air into the gas exchange zone.

Hyperventilation of the lungs, creating a hypocapnic bronchoconstrictor effect, increases the unevenness of ventilation of the lungs, violates the patency of the bronchi, forms elements of extensive hidden bronchial obstruction, which may be the main reason for the decrease in oxygen in arterial blood (arterial hypoxemia).


An oxygen supply in excess of physiological and normal rates for minute breathing volumes, for example, 10 liters per minute with a norm of 5.3 l/min, will always give a negative result and an increase in arterial hypercapnia, and the cause is hyperventilation of the lungs and hypocapnic (alveolar) bronchoconstrictor an effect sharply reducing the area of ​​gas exchange in the lungs.


At this stage of the disease, normalization of external respiration according to the method proposed by Dr. Buteyko normalizes bronchial patency, increases the gas exchange area, including through intact areas of the lungs, which is especially important with COVID-19 and normalizes arterial blood oxygenation in a natural way.

In most cases, the fact that the transition of oxygen from blood to cells is regulated by the pH of the blood, and not by the degree of saturation of the blood with oxygen, is overlooked.

Under normal conditions, hyperventilation of the lungs for 10 minutes, creating a deficiency of CO2 in the lungs and blood, leads to a change in blood pH and a violation of the dissociation of oxyhemoglobin, which leads to a paradoxical situation: the blood is completely saturated with oxygen, since gas exchange in the lungs is not disturbed, but oxygen does not enter the cells and  tissue, and cellular hypoxia occurs, which cannot be eliminated without normalizing the pH of the blood (Verigo-Bohr effect).


An insignificant clinical effect due to oxygen breathing may be due to an increase in oxygen in the blood plasma, while in order to effectively eliminate cellular hypoxia, it is necessary to normalize the blood pH and general ventilation.



4. Prevention of respiratory failure according to the method proposed by Dr. Buteyko


To prevent cellular hypoxia, arterial hypoxemia, cellular and arterial hypercapnia, it is enough to eliminate pulmonary hyperventilation and normalize external respiration according to the method proposed by Dr. Buteyko.


1. In the absence of damage to the lung tissue, gas exchange is normalized as a result of elimination of elements of latent bronchial obstruction, normalization of blood pH and normal dissociation of oxyhemoglobin.


2. In the event of damage to any area of ​​the lung tissue, gas exchange will be carried out in sufficient volume through healthy areas in the absence of latent bronchial obstruction and normal arterial blood pH.


Restore breathing through the nose in full, eliminate noisy and deep breathing through the mouth, put a patient with respiratory failure on his stomach to limit excursion of the chest and abdomen and to reduce pulmonary hyperventilation - these measures will have a greater positive effect than mechanical ventilation and oxygen therapy.

April 16, 2020



COVID-19, Buteyko breathing technics and corticosteroids in October 2020 (October 17, 2020)

Dr. Andrey Novozhilov, MD, Chief physician of the Buteyko Clinic in Moscow (since 1989), 

co-author of the Buteyko method, 

co-founder of the Buteyko Clinic in Moscow in 1987


October 17, 2020





Sorry, this article is in Russian only now







NOTE!

Make sure that anyone who demonstrates or teaches Buteyko breathing exercises has a Certificate of a specialist in the Buteyko method, confirming his qualifications, the validity of which does not exceed one year, otherwise the presented materials and recommendations are hazardous to health due to lack of professional education and many mistakes.

Make sure that any material (books, articles, video tutorials, etc.) describing or demonstrating Buteyko breathing exercises has on the first page the Preface of the copyright holders or the Consent to publication, otherwise such material usually contains errors, absurdities and poses a threat to health.




Видеоролик c YouTube: Аллергия и дерматит - лечение по Методу Бутейко без лекарств - www.buteykomoscow.ru



Полезно знать:

Метод Бутейко - это научное открытие, научное изобретение, а сегодня - это передовая медицинская технология, основанная на сложной  поэтапной безлекарственной нормализации функции дыхания, ч...

Метод Бутейко® является научным открытием и изобретением в области медицины. 
Как любая интеллектуальная собственность метод Бутейко®  защищен международным законом об авто...
Научное открытие
В 1952 году К.П.Бутейко впервые в медицине заявляет о существовании болезни глубокого дыхания и создает теорию ее развития. Оказалось, что при развитии многих заболеваний, таких ...
Данная работа представляет главный результат наблюдений динамики физиологических процессов в организме человека при нормализации стереотипа внешнего дыхания. Это направление исследований весьма важно ...
Бутейко Константин Павлович (1923 — 2003гг.) — известный ученый - физиолог, блестящий врач - клиницист, к.м.н., академик Международной Академии Информатизации (МАИ). Автор более 100 на...
1. Нормализация дыхания нормализует кислород - я лечу кислородом!
2. Какая функция самая важная? Нарушение дыхания - это удушье, а питания - понос. Без дыхания - живешь ...
Созданная мною теория патогенеза заболевания сахарным диабетом впервые была опубликована в журнале «Изобретатель и рационализатор» за 1962 г., № 5. Строго говоря, в журнальной статье изложена теория б...
Я с большим удовольствием выступаю в стенах нашего Университета, где мне пришлось в 1946 г. начать изучение медицины.
Только в общих чертах я изложу все основные закономерности, которые были на...